Remus Pharma's H1-FY26 consolidated PAT rose 33.97% to INR 17.50 Cr, with revenue up 46.80% to INR 400.20 Cr.

Remus Pharmaceuticals LimitedREMUS · Filed with the exchange

Operational highlights include tender wins in Nicaragua, 37 new product approvals, a new therapeutic segment launch, and market entry into Algeria.

No comments yet. Be the first.

More from Remus Pharmaceuticals Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.